|
John P. McLaughlin has served as a Director since June 2007. Since January 2000, Mr. McLaughlin has been Chief Executive Officer and a member of the Board of Directors of Anesiva, Inc., a biotechnology company developing therapies to treat pain. Prior to Anesiva, he was President of Tularik, and before that spent 11 years at Genentech in a number of senior management positions including Executive Vice President. Previously, Mr. McLaughlin represented major pharmaceutical companies as a partner in a Washington, D.C. law firm that specializes in food and drug law and served as legal counsel to various subcommittees at the U.S. House of Representatives, drafting numerous measures that became U.S. Food and Drug Administration laws. Mr. McLaughlin was also co-founder and Chairman of Eyetech Pharmaceuticals, which was acquired by OSI Pharmaceuticals in 2005. He earned a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America.
| 